Mylan deal puts future of its beleaguered EpiPen in spotlight - (Fidelity via NewsPoints Desk)

  • Despite being bolstered by an agreement to merge with Pfizer's off-patent branded drug business, Mylan remains under pressure due to ongoing shortages of EpiPen, as reported.

  • Although Pfizer's Meridian Medical Technologies unit has manufactured EpiPen for Mylan for several years, it is unclear whether the merger will lessen the shortages.

  • A Pfizer spokeswoman noted that although the agreement will not merge Meridian with Mylan, the drugmakers are in talks to transfer the contract manufacturer to the newly created generics company.

  • "We've had some conversations with Mylan about that potentially transferring to Mylan as a supplement to the existing transaction, but nothing has been finalised to date yet," cautioned Pfizer chief financial officer Frank D'Amelio.

  • Commenting on the news, Edward Jones analyst Ashtyn Evans remarked "over the long term, having all EpiPen operations under one unified company would reduce complexity."

  • Meanwhile, several companies, including Amneal Pharmaceuticals, Kaléo, Novartis and Teva, have launched generic versions of EpiPen.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.